Interactions of the “piano‐stool” [ruthenium(II) (η6‐arene)(en)CL]+ complexes with water and nucleobases; ab initio and DFT study
暂无分享,去创建一个
Jaroslav V. Burda | Jirí Sponer | Zdenek Futera | Julia Klenko | Judit E. Sponer | J. Šponer | J. Šponer | Z. Futera | J. Burda | Julia Klenko | Zdeněk Futera
[1] P. Dyson,et al. Is the Aromatic Fragment of Piano‐Stool Ruthenium Compounds an Essential Feature for Anticancer Activity? The Development of New RuII‐[9]aneS3 Analogues , 2005 .
[2] Erwin P. L. van der Geer,et al. Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[3] A. Klamt,et al. COSMO : a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient , 1993 .
[4] Jerzy Leszczynski,et al. How strong can the bend be on a DNA helix from cisplatin? DFT and MP2 quantum chemical calculations of cisplatin-bridged DNA purine bases. , 2003, Inorganic chemistry.
[5] V. Brabec,et al. Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media , 2001, JBIC Journal of Biological Inorganic Chemistry.
[6] P. Sadler,et al. Insights into the mechanism of action of platinum anticancer drugs from multinuclear NMR spectroscopy , 2006 .
[7] L. Ji,et al. Enantiomeric ruthenium(II) complexes binding to DNA: binding modes and enantioselectivity , 2000, JBIC Journal of Biological Inorganic Chemistry.
[8] J. Lau,et al. Hydrolysis of the Anticancer Drug Cisplatin: Pitfalls in the Interpretation of Quantum Chemical Calculations. , 2006, Journal of chemical theory and computation.
[9] Jerzy Leszczynski,et al. Activation barriers and rate constants for hydration of platinum and palladium square-planar complexes: an ab initio study. , 2004, The Journal of chemical physics.
[10] Richard A Friesner,et al. Theoretical study on the stability of N-glycosyl bonds: why does N7-platination not promote depurination? , 2002, Journal of the American Chemical Society.
[11] B. Nordén,et al. Binding of delta- and lambda-[Ru(phen)3]2+ to [d(CGCGATCGCG)]2 studied by NMR. , 1994, Biochemistry.
[12] Antonio Fernández-Ramos,et al. DOIT: a program to calculate thermal rate constants and mode‐specific tunneling splittings directly from quantum‐chemical calculations , 2001, J. Comput. Chem..
[13] James A. Platts,et al. Hydrogen bonding, solvation, and hydrolysis of cisplatin: A theoretical study , 2004, J. Comput. Chem..
[14] P. Sadler,et al. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts. , 2003, Chemistry.
[15] P. Geerlings,et al. Quantum similarity study of atoms: a bridge between hardness and similarity indices. , 2007, The Journal of chemical physics.
[16] J. Lau,et al. Loss of amine from platinum(II) complexes: implications for cisplatin inactivation, storage, and resistance. , 2005, Chemistry.
[17] B. Keppler,et al. Synthesis of water-soluble ruthenium porphyrins as DNA cleavers and potential cytotoxic agents , 1997, JBIC Journal of Biological Inorganic Chemistry.
[18] P. Sadler,et al. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. , 2006, Journal of medicinal chemistry.
[19] I. Tavernelli,et al. Rational design of organo-ruthenium anticancer compounds , 2005 .
[20] P. Sadler,et al. Formation of platinated GG cross-links on DNA by photoactivation of a platinum(IV) azide complex , 2003, JBIC Journal of Biological Inorganic Chemistry.
[21] L. Marzilli,et al. New Concepts Relevant to Cisplatin Anticancer Activity from Unique Spectral Features Providing Evidence That Adjacent Guanines in d(GpG), Intrastrand-Cross-Linked at N7 by a cis-Platinum(II) Moiety, Can Adopt a Head-to-Tail Arrangement , 1999 .
[22] J. Cummings,et al. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer , 2002, British Journal of Cancer.
[23] K. Dunbar,et al. Reactivity studies of anticancer active dirhodium complexes with 2-aminothiophenol. , 2002, Inorganic chemistry.
[24] I. Tavernelli,et al. Binding of Organometallic Ruthenium(II) and Osmium(II) Complexes to an Oligonucleotide: A Combined Mass Spectrometric and Theoretical Study , 2005 .
[25] B. Nordén,et al. DNA Binding Geometries of Ruthenium(II) Complexes with 1,10-Phenanthroline and 2,2‘-Bipyridine Ligands Studied with Linear Dichroism Spectroscopy. Borderline Cases of Intercalation , 1998 .
[26] Stephen Neidle,et al. Principles of nucleic acid structure , 2007 .
[27] J. Šponer,et al. A Systematic ab Initio Study of the Hydration of Selected Palladium Square-Planar Complexes. A Comparison with Platinum Analogues , 2001 .
[28] P. Sadler,et al. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts. , 2002, Journal of the American Chemical Society.
[29] A. Klamt. Conductor-like Screening Model for Real Solvents: A New Approach to the Quantitative Calculation of Solvation Phenomena , 1995 .
[30] M. Sip,et al. Pentacoordinated transition states of cisplatin hydrolysis— ab initio study , 2000 .
[31] Bernhard Lippert,et al. Cisplatin : chemistry and biochemistry of a leading anticancer drug , 2006 .
[32] P. Sadler,et al. Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. , 2003, Journal of the American Chemical Society.
[33] H. Stoll,et al. Energy-adjustedab initio pseudopotentials for the second and third row transition elements , 1990 .
[34] Jaroslav V Burda,et al. Cisplatin interaction with cysteine and methionine, a theoretical DFT study. , 2005, Journal of inorganic biochemistry.
[35] F. Caruso,et al. Antitumor titanium compounds. , 2003, Mini reviews in medicinal chemistry.
[36] N. Katsaros,et al. Rhodium and its compounds as potential agents in cancer treatment. , 2002, Critical reviews in oncology/hematology.
[37] M. Sabat,et al. Model of the Second Most Abundant Cisplatin-DNA Cross-Link: X-ray Crystal Structure and Conformational Analysis of cis-[(NH(3))(2)Pt(9-MeA-N7)(9-EtGH-N7)](NO(3)).2H(2)O (9-MeA = 9-Methyladenine; 9-EtGH = 9-Ethylguanine). , 1996, Inorganic chemistry.
[38] A. Wang,et al. Molecular structure of the complex formed between the anticancer drug cisplatin and d(pGpG): C222(1) crystal form. , 1990, Journal of biomolecular structure & dynamics.
[39] J. Leszczynski,et al. The influence of a sugar-phosphate backbone on the cisplatin-bridged BpB′ models of DNA purine bases. Quantum chemical calculations of Pt(II) bonding characteristics , 2004 .
[40] B. Nordén,et al. Interactions of Tris(phenanthroline)ruthenium(II) Enantiomers with DNA: Effects on Helix Flexibility Studied by the Electrophoretic Behavior of Reptating DNA in Agarose Gel† , 2000 .
[41] G. Erker,et al. Bioorganometallic Chemistry: Reactions of Methyltitanocene Cation Complexes with a Singly Deprotected Methyl Glucopyranoside , 2005 .
[42] James A Platts,et al. Hydrogen bonding and covalent effects in binding of cisplatin to purine bases: ab initio and atoms in molecules studies. , 2005, Inorganic chemistry.
[43] B. Keppler,et al. Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and HInd trans-[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS , 2001, JBIC Journal of Biological Inorganic Chemistry.
[44] J. Lau,et al. In silico evolution of substrate selectivity: comparison of organometallic ruthenium complexes with the anticancer drug cisplatin. , 2006, Chemical communications.
[45] P. Sadler,et al. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media. , 2003, Biochemistry.
[46] Jerzy Leszczynski,et al. The influence of square planar platinum complexes on DNA base pairing. An ab initio DFT study , 2001 .
[47] Jerzy Leszczynski,et al. Hydration process as an activation of trans‐ and cisplatin complexes in anticancer treatment. DFT and ab initio computational study of thermodynamic and kinetic parameters , 2005, J. Comput. Chem..
[48] Chuanbao Zhu,et al. Theoretical study of cisplatin binding to DNA: the importance of initial complex stabilization. , 2005, The journal of physical chemistry. B.
[49] P. Lincoln,et al. AB INITIO AND SEMIEMPIRICAL CALCULATIONS OF GEOMETRY AND ELECTRONIC SPECTRA OF RUTHENIUM ORGANIC COMPLEXES AND MODELING OF SPECTROSCOPIC CHANGES UPON DNA BINDING , 1997 .
[50] James A Platts,et al. A QM/MM study of cisplatin-DNA oligonucleotides: from simple models to realistic systems. , 2006, Chemistry.
[51] Calculations of hydrated titanium ion complexes: structure and influence of the first two coordination spheres , 2001 .
[52] Michael Dolg,et al. Ab initio energy-adjusted pseudopotentials for elements of groups 13-17 , 1993 .
[53] X. You,et al. Hydrolysis theory for cisplatin and its analogues based on density functional studies. , 2001, Journal of the American Chemical Society.
[54] Anna F. A. Peacock,et al. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions. , 2006, Journal of the American Chemical Society.
[55] Rafa Wysokiski,et al. The performance of different density functional methods in the calculation of molecular structures and vibrational spectra of platinum(II) antitumor drugs: cisplatin and carboplatin , 2001, J. Comput. Chem..
[56] J. Platts,et al. Insights into DNA binding of ruthenium arene complexes: role of hydrogen bonding and pi stacking. , 2008, Inorganic chemistry.
[57] J. Leszczynski,et al. The interactions of square platinum(II) complexes with guanine and adenine: a quantum-chemical ab initio study of metalated tautomeric forms , 2000, JBIC Journal of Biological Inorganic Chemistry.
[58] R. Bader. Atoms in molecules : a quantum theory , 1990 .
[59] R. Parr,et al. Absolute hardness: companion parameter to absolute electronegativity , 1983 .
[60] J. Burda,et al. Pt-bridges in various single-strand and double-helix DNA sequences. DFT and MP2 study of the cisplatin coordination with guanine, adenine, and cytosine , 2007, Journal of molecular modeling.
[61] J. Asara,et al. Evidence for Binding of Dirhodium Bis-Acetate Units to Adjacent GG and AA Sites on Single-Stranded DNA , 2000 .
[62] J. Reedijk. Why does Cisplatin reach Guanine-n7 with competing s-donor ligands available in the cell? , 1999, Chemical reviews.
[63] Peddaiahgari Seetharamulu,et al. Comprehensive ab initio quantum mechanical and molecular orbital (MO) analysis of cisplatin: Structure, bonding, charge density, and vibrational frequencies , 1999, J. Comput. Chem..
[64] U. Rothlisberger,et al. Cisplatin binding to DNA oligomers from hybrid Car-Parrinello/molecular dynamics simulations , 2004 .
[65] Dirk V Deubel,et al. The chemistry of dinuclear analogues of the anticancer drug cisplatin. A DFT/CDM study. , 2006, Journal of the American Chemical Society.
[66] E. Thiel,et al. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[67] David J. Williams,et al. Potential multifunctional anti-cancer metal complexes II. Synthesis of some rhodium(II) and platinum(II) complexes of diamine-substituted acridine-4-carboxamides, and the X-ray structure of [Rh(CH3CO2)2L]2 (L=N-[2-(dimethylamino)hexyl]acridine-4-carboxamide) , 1990 .
[68] Richard A Friesner,et al. Theoretical study of cisplatin binding to purine bases: why does cisplatin prefer guanine over adenine? , 2003, Journal of the American Chemical Society.
[69] Dirk V Deubel,et al. Factors governing the kinetic competition of nitrogen and sulfur ligands in cisplatin binding to biological targets. , 2004, Journal of the American Chemical Society.
[70] W. Rocha,et al. Monte Carlo simulation of cisplatin molecule in aqueous solution. , 2006, The journal of physical chemistry. B.
[71] M. Sundaralingam,et al. Structure of the anti-cancer drug complex tetrakis (mu-acetato)-bis(1-methyladenosine)dirhodium(II) monohydrate. , 1991, Acta Crystallographica Section C: Crystal Structure Communications.
[72] B. Nair,et al. Synthesis, characterization and DNA binding studies of a ruthenium(II) complex. , 2002, Journal of inorganic biochemistry.
[73] H. D. Dos Santos,et al. Structure and properties of the 5a,6-anhydrotetracycline-platinum(II) dichloride complex: a theoretical ab initio study. , 2006, Journal of inorganic biochemistry.
[74] W. Rocha,et al. Linear free energy relationship for 4-substituted (o-phenylenediamine)platinum(II) dichloride derivatives using quantum mechanical descriptors. , 2005, Journal of inorganic biochemistry.